ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…
Biotechnology
US, Waltham [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about ImmunoGen, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -0.8300 | -0.480 | 59 | 356 | -71 | -33 | -71 | -26 | -178 | -33 | 24 | 33 |
| 2015 | -0.7100 | -0.670 | 85 | 38 | -60 | 0.83 | -55 | 8 | -166 | 0.22 | 28 | 23 |
| 2016 | -1.6500 | -1.260 | 60 | 53 | -143 | -112 | -123 | -92 | -270 | -97 | 36 | 28 |
| 2017 | - | -1.480 | - | 41 | - | -120 | - | -100 | - | -103 | - | 30 |
| 2018 | -0.9800 | -0.850 | 115 | 156 | -96 | -117 | -55 | -88 | -197 | -71 | 33 | 41 |
| 2019 | -1.2000 | -1.230 | 53 | 51 | -167 | -163 | -153 | -146 | -330 | -156 | 36 | 35 |
| 2020 | -0.8200 | -0.770 | 82 | 114 | -122 | -86 | -65 | -58 | -185 | -70 | 38 | 49 |
| 2021 | -0.3800 | -0.450 | 132 | 92 | -66 | 30 | -19 | 74 | -135 | 67 | 38 | 67 |
| 2022 | -0.8800 | -0.740 | 108 | 74 | -222 | -174 | -217 | -156 | -220 | -157 | 116 | 56 |
| 2023 | -0.8800 | -0.050 | 108 | 357 | -222 | -73 | -217 | -179 | -220 | -180 | 116 | 78 |
| 2024 | - | 0.050 | - | 493 | - | 17 | - | -178 | - | -179 | - | 77 |
| 2025 | - | 0.348 | - | 538 | - | 104 | - | -424 | - | -538 | - | 330 |
| 2026 | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |